EHang's Flying Taxi Story Just Hit Four Straight Downgrades — and the Bulls Are Still Talking About Guinness World Records

Here's a fun exercise: pull up eight analyst price targets on EHang right now and try to find the through-line. J.P. Morgan says $4.40. Bank of America says $5.40. Goldman says $7.30. Morgan Stanley says $7.70. UBS, somehow, still says $11.00. Average it all together and you get a "consensus" of $11.43 against a stock trading around $6.33 — a headline number implying 128% upside that's really just eight people staring at the same regulatory fog and guessing wildly different distances to the exit.

That's the state of play with EH after one of the uglier stretches an eVTOL story has had this year: three sell-side downgrades in a ten-day window between July 4th and July 14th (JPMorgan, BofA, Goldman), stacked on top of a UBS downgrade from early June. Four major shops turning cautious in six weeks isn't noise. That's a pattern, and the pattern has a name: regulatory delay.

The Thesis Was Always "Wait for the Government"

EHang's bull case has never really been a product problem — it's the only company on earth with a type certificate, production certificate, and standard airworthiness certificate for a pilotless eVTOL. That part's real. The two operating carriers, EHang General Aviation and Heyi Aviation, have run over 3,000 flight missions with zero accidents and zero violations. Genuinely impressive engineering and safety record.

The problem is that "commercially certified" and "commercially operating at scale" are two very different sentences, and the gap between them is entirely occupied by the CAAC and local regulators in Hefei and Guangzhou. Every downgrade this month cites the same thing: certification didn't convert into ticketed public flights on the timeline the Street had modeled. BofA didn't just downgrade — it cut 2026-2028 sales volume estimates by 11-18%. That's not a sentiment adjustment; that's an analyst admitting the model was wrong about the pace of the actual business.

The Buyback Timing Is a Little Too Cute

Company reaffirms RMB 600 million full-year guidance, announces a $30 million share repurchase — then reports Q1 revenue of just CNY 25.7 million against a CNY 126.4 million net loss, a day after the buyback hit the wires. Read that sentence again. A buyback funded out of RMB 1.03 billion in cash is a legitimate signal of confidence, sure, but it's also a well-worn move for a stock that needed a headline to offset a rough print. The market's initial reaction was mixed at best. I'm not saying it's cynical. I'm saying the timing wasn't an accident.

What the Chart Actually Shows

Strip away the narrative and the stock is sitting near 52-week lows, technically oversold, with support around $5.97 and resistance up near $13.80. Directional accuracy on short-term price models here is reportedly around 14% — which is a polite way of saying nobody's technical read on this name is worth much right now. This is a stock trading on headlines, not charts. Fundamentals aren't helping the case either: gross margins look fine at 61.5%, but net margins are deeply negative, debt-to-equity sits at a chunky 57.2x, and the cash runway, while not immediately alarming, isn't the kind of cushion that lets you absorb multiple more quarters of regulatory drift.

Where This Leaves You

There's a real, credible growth story buried in here — global expansion into Mexico and Thailand, 40+ operational sites in China, a Hong Kong Low-Altitude Economy Sandbox selection that could eventually validate the whole commercial model outside mainland bureaucracy. If that sandbox trial delivers something concrete, this stock re-rates hard, because the certification moat is real and Joby and Archer aren't exactly cruising either.

But "if" is doing enormous work in that sentence, and right now the Street's own price targets can't agree within a factor of two-and-a-half. That's not a mispricing you trade with conviction — that's a market that genuinely doesn't know what this business is worth until Beijing and Hefei tell it what's allowed.

The call here: small position, if any, sized for a binary regulatory catalyst — not a valuation call. Invalidation is a clean break of $5.97. Anyone buying the "128% upside" headline without reading why four analysts just cut their targets is buying the story, not the stock.